1. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metbol. 2014;32 Suppl 4:337–50.
2. Zhou D, Zheng H, Wang C, Shi D, Li J. Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. BMC Musculoskelet Disord. 2014;15 Suppl 1:239–45.
3. Ioannidis G, Pallan S, Papaioannou A, Mulgund M, Rios L, Ma J, et al. Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos. 2014;9 Suppl 1:1–8.
4. Van Helvoort AL, Van Norren K, Gros-Van Hest M, Lansink M, inventors; Van Helvoort Adrianus Lambertus Bertholdus, Van Norren Klaske, assignee. Use of one or members selected from the group consisting of apigenin, luteolin, morin and functional analogues thereof for manufacture of a preparation for the treatment and/or prevention of disorder related to altered bone metabolism in a mammal. United States patent application US 10/472,438. Accessed 22 Mar 2002.
5. Colbin A. Whole-food Guide to Strong Bones: A Holistic Approach. New Harbinger Publications. 2009.